Neuphoria Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Neuphoria Therapeutics Inc (NEUP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Neuphoria Therapeutics Inc vs Its Competitors
- Profitability: Its -417.7% net margin compares with -882.8% for the peer group.
- Scale: Neuphoria Therapeutics Inc ranks #383 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Neuphoria Therapeutics Inc accounted for 44.3% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NEUP Sales vs. its Competitors, Q4 2026
With a net margin of -417.70 %, Neuphoria Therapeutics Inc achieved higher profitability than its competitors (-882.79 %).
Neuphoria Therapeutics Inc generated 44.31 % of the combined sales of its peer group.
Neuphoria Therapeutics Inc vs. its Competitors, Q4 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Neuphoria Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Neuphoria Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Neuphoria Therapeutics Inc's competitor groups requires a Commercial License.
Neuphoria Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Neuphoria Therapeutics Inc | - | - | - | No |
| Competitors combined (1) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NEUP Stock Performance relative to its Competitors
NEUP Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Vistagen Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Neuphoria Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Neuphoria Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Neuphoria Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Neuphoria Therapeutics Inc | 15.25 | - |
| Vistagen Therapeutics Inc | 12.08 | 2.50 |
| SUBTOTAL | 27.33 | 2.50 |
Sources: Neuphoria Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Neuphoria Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Neuphoria Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Vistagen Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Neuphoria Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Neuphoria Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Neuphoria Therapeutics Inc | 15 | - | - |
| Vistagen Therapeutics Inc | 12 | 61,000 | -1,649,268 |
| PEERS TOTAL | 12 | 61,000 | -1,649,268 |
Neuphoria Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Neuphoria Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Neuphoria Therapeutics Inc ranks #383 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 821, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,021,365 | 19.25 % |
| 2 | Johnson and Johnson | 624,739 | 11.78 % |
| 3 | Beone Medicines Ltd | 539,025 | 10.16 % |
| 4 | Abbvie Inc | 465,454 | 8.77 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 383 | Neuphoria Therapeutics Inc | 15 | 0.00 % |
Market cap and industry share for the rest of Neuphoria Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-02.
Neuphoria Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 378 | Lipocine Inc | 17 | -29.12 % |
| 379 | Allarity Therapeutics Inc | 17 | -35.19 % |
| 380 | Kiora Pharmaceuticals Inc | 16 | - |
| 381 | Cocrystal Pharma Inc | 16 | -7.14 % |
| 382 | Pasithea Therapeutics Corp | 1,234 | 12.3% |
| 383 | Neuphoria Therapeutics Inc | 15 | -74.08 % |
| 384 | Transcode Therapeutics Inc | 1,234 | 12.3% |
| 385 | Aeon Biopharma inc | 1,234 | 12.3% |
| 386 | Citius Pharmaceuticals Inc | 1,234 | 12.3% |
| 387 | Synlogic Inc | 1,234 | 12.3% |
| 388 | Lisata Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Neuphoria Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-02. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Neuphoria Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 0.9x | 4.5x | -3.6x |
| Return on Equity | -55.91 % | industry aggregate | -73.16 % |
| Return on Invested Capital | -30.64 % | -2.89 % (avg) | -27.75 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Neuphoria Therapeutics Inc's BCG Growth-Share Matrix
Relative market share (vs Neuphoria Therapeutics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Neuphoria Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Neuphoria Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 821 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Neuphoria Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Neuphoria Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Neuphoria Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Neuphoria Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Neuphoria Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 73.2 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Neuphoria Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Neuphoria Therapeutics Inc | 7.54 | 8.02 | - |
| Vistagen Therapeutics Inc | 3.83 | 4.82 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Neuphoria Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Neuphoria Therapeutics Inc | Q2 2026 | - | - |
| Vistagen Therapeutics Inc | Q2 2026 | +504.9 % | - |
| PEERS TOTAL | +1,048.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Neuphoria Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Neuphoria Therapeutics Inc | Q2 2026 | - | - |
| Vistagen Therapeutics Inc | Q2 2026 | - | - |
Neuphoria Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Neuphoria Therapeutics Inc | - | - | - |
| Vistagen Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Neuphoria Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Neuphoria Therapeutics Inc | - | - |
| Vistagen Therapeutics Inc | - | 4.83 |
| PEERS AVERAGE | - | 10.93 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.